Close Menu

NEW YORK (GenomeWeb News) – Cancer molecular diagnostics firm Cernostics has filed a document with the US Securities and Exchange Commission saying it plans to raise $500,000.

The Pittsburgh-based company, which also has offices in Danville, Penn., did not respond to a request for comment, but in its Form D, it said that it raised $125,000 toward its targeted amount. Securities offered as part of the raise include debt, options, warrants to acquire other securities, and securities to be acquired upon exercise of option, warrants, or other rights to acquire securities.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.